| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.003 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.005 |